Randomized clinical trials: Slow death by a thousand unnecessary policies?

Ferris, Lorraine E.; Naylor, C. David
October 2004
CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p892
Academic Journal
Focuses on financial conflicts of interest between researchers and industry sponsors in conducting clinical trials. Roles of researchers in clinical trials; Purpose of pharmaceutical companies in conducting their own clinical trials; Susceptibility of preapproval studies by pharmaceutical industries to business imperatives; Demand for appropriate physician remuneration in clinical studies; Concerns on overregulation and bureaucracy on clinical trials.


Related Articles

  • Physician remuneration in industry-sponsored clinical trials: the case for standardized clinical trial budgets. Ferris, Lorraine E.; Naylor, C. David // CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p883 

    Presents an analysis of the reasonable and just remuneration for physicians involved in industry-sponsored clinical trials in Canada. Principles of reasonable physician remuneration reinforced by the Canadian Medical Association Policy on Physicians and the Pharmaceutical Industry; Categories...

  • Trials & tribulations. Reese, Shelly // Medical Economics;10/17/2008, Vol. 85 Issue 20, p16 

    The article focuses on the increasing cost for clinical research and the proper attitude for successful clinical trials. It is observed that cost for clinical trials has increased from 2004-2007. It states that clinical investigators needs a dedicated support staff and understanding surrounding...

  • Experts emphasize need for speed in launch of Australian trials. Morgan, Branwen // Nature Medicine;May2011, Vol. 17 Issue 5, p521 

    The article reports on the need for a faster launch in conducting clinical trials of drugs in Australia. It mentions that the number of new trials recorded in the country has decreased to 574 due to higher operating costs and competition from the emerging countries. To address the issue, it...

  • The delay in sharing research data is costing lives. Sommer, Josh // Nature Medicine;Jul2010, Vol. 16 Issue 7, p744 

    In this article, the author reflects on release of life-saving research. The author points out that scientists need enough money and resources to initiate and publish results of their clinical trials and other studies on life science. The author asserts that financial support is highly needed to...

  • Delays in publication of cost utility analyses conducted alongside clinical trials:registry analysis. Greenberg, Dan; Rosen, Allison B.; Olchanski, Natalia V.; Stone, Patricia W.; Nadai, John; Neumann, Peter J. // BMJ: British Medical Journal (International Edition);6/26/2004, Vol. 328 Issue 7455, p1536 

    Presents a paper on the delays in publication of cost utility analyses conducted alongside clinical trials. Recent decision by this journal to accept economic evaluations for publication provided they are conducted alongside clinical trials; Study to determine the time lag between the...

  • UK is losing market share in pharmaceutical research. Smith, Richard // BMJ: British Medical Journal (International Edition);10/28/2000, Vol. 321 Issue 7268, p1041 

    Discusses the efforts of Great Britain's pharmaceutical industry to make research and development in London more attractive to clinical research funders. Extent of industry spending on research in the National Health Service (NHS); Factors affecting the declining quality of British medical...

  • Industry Funding of Clinical Trials: Benefit or Bias? Chopra, Sameer S. // JAMA: Journal of the American Medical Association;7/2/2003, Vol. 290 Issue 1, p113 

    Focuses on the ethical concerns relating to clinical trials which are funded by pharmaceutical companies. Discussion of whether there is a conflict of interest when people with a financial interest in the outcome of clinical trials are involved in conducting them; Role of clinical trials in...

  • Some industry-funded reviews show discrepancy between data, conclusions. Brockenbrough, Gina // Orthopedics Today;Feb2008, Vol. 28 Issue 2, p82 

    The article discusses research being done on meta-analyses on drugs funded by a single drug company. It references a study by Veronica Yank, D. Rennie and L. A. Bero, published in the 2007 issue of the "British Journal of Medicine." According to the article, the researchers found that...

  • Phase III Failures: What Can Be Done? Beltangady, Mohan // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p82 

    Looks at what can be done to prevent failures in Phase III clinical trials. Increasing costs of drug development; Possible reasons for why Phase III trials may fail to confirm what has been learned from Phase II studies; Value of flexible trial designs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics